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Background: In a malignant tumour, cancer cells are embedded in stromal cells, namely cancer-associated
fibroblasts (CAFs). These CAFs are now accepted as important players in cancer dynamics, being involved in tumour
growth and progression. Although there are various reports on the interaction between tumour and stromal cells,
the clinico-pathological significance of this cross-talk is still largely unknown. In this study, we aimed to characterise
the expression of key metabolic proteins involved in glucose transport, pyruvate/lactate shuttle system, glycolytic
metabolism and fatty acid oxidation in CAFs and tumour cells in different stages of malignant transformation. We
further aimed to contextualise the clinico-pathological significance of these protein expression profiles with
reference to known prognostic indicators, including biochemical recurrence in pT stage.
Methods: Prostate tissues were obtained from 480 patients with a median age of 64 years following radical
prostatectomy with no previous hormonal therapy. Tissues were analysed for the expression of several key
metabolism-related proteins in glands and surrounding fibroblasts by immunohistochemistry. Reliable markers of
prognosis such as pT stage and biochemical recurrence were assessed for each case.
Results: We observed that prostate cancer cells did not rely mainly on glycolytic metabolism, while there was a
high expression of MCT4 and CAIX - in CAFs. This corroborates the hypothesis of the “Reverse Warburg effect” in
prostate cancer, in which fibroblasts are under oxidative stress and express CAIX, an established hypoxia marker. We
found that alterations in the expression of metabolism-related proteins were already evident in the early stages of
malignant transformation, suggesting the continuing alteration of CAFs from an early stage. Additionally, and for
the first time, we show that cases showing high MCT4 expression in CAFs with concomitant strong MCT1 expression in
prostate cancer (PCa) cells are associated with poor clinical outcome, namely pT3 stage of the tumour.
Conclusions: In summary, this work demonstrates for the first time the clinico-pathological significance of the lactate
shuttle in prostate cancer. It also suggests that other alterations in CAFs may be useful prognostic factors, and further
supports the use of MCT1/MCT4 as targets for PCa therapy.
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It is well established that solid tumours, including pros-
tate cancer, exist under fluctuating oxygen tension, dur-
ing which they are intermittently exposed to hypoxia
[1,2]. Under hypoxic conditions, tumour cells primarily
use glycolysis for energy, producing lactate, which is
expelled to the tumour microenvironment, allowing tu-
mours to continue their glycolytic activity [3,4]. Re-
cently, Sonveaux et al. showed that lactate, which is
generally considered a waste product, is preferred over
glucose by oxidative tumour cells as their primary en-
ergy source [5].
Monocarboxylate transporters (MCTs) have been shown
to play an important role in various tumours [6]. However,
since they facilitate the transport of lactate in and out of
cells, their role in this stromal/epithelial cell symbi-
osis is also attracting interest. MCT1 is a high-affinity
transporter and its expression seems to be regulated
by multiple signalling pathways, micro-environmental
parameters, changes in substrate concentration and pH
[7]. MCT4 is a low-affinity transporter, which is abundant
in highly glycolytic muscle cells and is one of the many
target genes of hypoxia-inducible factor 1 alpha (HIF-1α)
[8]. Other targets of HIF-1α include glucose transporter-1
(GLUT-1), the main transporter involved in glucose up-
take [9,10]; lactate dehydrogenase V (LDHV), which is
responsible for the conversion of pyruvate into lactate;
pyruvate dehydrogenase kinase isozyme 1 (PDK1), which
is responsible for the phosphorylation and consequent in-
activation of pyruvate dehydrogenase (PDH); and carbonic
anhydrase IX (CAIX), a hypoxia-related protein involved
in pH regulation [11]. Alpha-methylacyl-CoA racemase
(AMACR), pristanoyl-CoA oxidase (ACOX-3) and D-
bifunctional protein (DBP), are also important fatty acid
oxidation-related proteins in prostate cancer [12,13], and
we also included them in our analysis.
The importance of a lactate shuttle system between
cancer cells and surrounding stroma has been described
in various tumour types [14-16], but its significance in
prostate cancer is not clear [17,18].
In this study, we aimed to identify a metabolic inter-
action between CAFs and prostate cancer cells, by ana-
lysing the expression of key metabolism-related proteins
in CAFs in relation to prostate cancer using prostate tis-
sue samples. We also assessed the clinico-pathological
significance of this expression to investigate a possible
CAF signature for PCa progression.
Methods
Patient sample selection
Formalin–fixed paraffin embedded tissues from 480 pros-
tate cancer patients were retrieved from the archives
of the Department of Pathology of Centro Hospitalar
do Porto, Portugal. Stroma surrounding non-neoplasticglands, prostatic intra-epithelial hyperplasia (PIN) lesions
and malignant glands were also analysed. Prostate cancer
patients were selected for the study according to the fol-
lowing criteria: availability of both tumour and normal tis-
sue for each patient, presence of adequate amount of
stroma in both normal and tumour tissues for efficient
selection for tissue microarray construction (TMA),
and absence of chemotherapy or radiotherapy. Prior to
TMA construction, tissue morphology was assessed on
HE slides. Data for clinical parameters significant in pa-
tient outcome were available, including pre-operative
serum total PSA, clinical stage, perineural invasion and
biochemical recurrence.
Ethics
The work has been approved by DEFI (Departamento de
Ensino Formação e Investigação) Ethics Committee of
Centro Hospitalar do Porto ref. no. 017/08(010-DEFI/
015-CES).
Immunohistochemistry
Samples organised into TMAs including 203 non-
neoplastic, 176 PIN and 480 neoplastic tissues were ana-
lysed for MCT1, MCT4, GLUT-1, GLUT-12, LDHV,
PDK1, CAIX, AMACR, ACOX-3 and DBP expression.
Staining was evaluated using a combined score system,
as previously described [19]. Detailed information re-
garding the immunohistochemistry (IHC) technique is
given in Table 1.
Immunohistochemical evaluation
IHC evaluation was performed as previously described
[19] and scored independently by two pathologists (JRV,
CL), blinded to the target under study. For statistical
purposes, only moderate and strong immunoreaction
final scores were considered positive. Discordant cases
were discussed in order to agree on a final score.
Statistics
Statistical analysis was performed using the SPSS sta-
tistical software (version 17.0, SPSS Inc., Chicago, IL,
USA). All comparisons were examined for statistical sig-
nificance using Pearson’s chisquare (χ2) test, using a
threshold for significance of p < 0.05. Figure 1 was gen-
erated in part using R statistical computing environ-
ment, R version 3.0.0 [20] The code for the aesthetics of
the stacked bar graphs was originally written by Kim
Herzig [21].
Results
We observed obvious differences between the expression
of key metabolism-related proteins in CAFs and tumour
cells (Figure 1). MCT1, MCT4, LDHV, PDK1, GLUT-1,
GLUT-12, CAIX, AMACR, ACOX-3 and DBP were
Table 1 Details of the immunohistochemical procedure used to analyze the expression of the different proteins
Protein Antibody Company Antibody dilution Positive control Incubation period Detection system
MCT4 sc-50329 Santa Cruz Biotechnology 1:500 Colon tumor Overnight R.T.U. Vectastain Universal Elite
ABC Kit, Vector, EUA
GLUT1 ab 15309 Abcam 1:2000 Head and neck tumor
2 hours
Ultravision Detection System
Anti-polyvalent, HRP, Labvision
Corporation, Freemont, CA
CAIX ab 15086 Abcam 1:2000 Stomach
MCT1 sc-365501 Santa Cruz Biotechnology 1:500 Colon tumor Overnight R.T.U. Vectastain Universal Elite
ABC Kit, Vector, EUA
GLUT12 ab 75441 Abcam 1:500 Kidney Overnight
LDHV ab 53010 Abcam 1:1000 Colon tumor
2 hours Ultravision Detection System
Anti-polyvalent, HRP, Labvision
Corporation, Freemont, CA
PDK1 ab 110025 Abcam 1:500 Stomach
AMACR 504R-16 Cell Marque 1:50 Kidney
ACOX3 sc-135435 Santa Cruz Biotechnology 1:250 Liver
DBP DBP antibody was a gift from
Dr. Gabriele Moller from
HelmholtzZentrum mÜnchen
Ready to use Kidney
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cells, while MCT1, LDHV, GLUT-1, GLUT-12, AMACR,
ACOX-3 and DBP were exclusively expressed in pros-
tate cancer cells. MCT4 and CAIX were expressed more
strongly in CAFs, and PDK1 stained both malignant
glands and CAFs.
Additionally, we assessed whether fibroblasts exhibited
differences in protein expression across different stages
of malignant transformation by analysing the expres-
sion of the same proteins in fibroblasts surrounding
benign glands (benign-associated fibroblasts; BAFs),
PIN-associated fibroblasts (PAFs) and CAFs. Figure 2
shows stacked bar graphs representing the expression
of MCT4, PDK1 and CAIX in more detail, since these
proteins were the ones exhibiting a clear expression
in fibroblasts surrounding both benign and malignant
glands. A statistically significant increase in both MCT4Figure 1 Comparison between metabolism-related proteins expressioand PDK1 expression in CAFs compared to BAFs was ob-
served (both p < 0.001). Curiously, CAIX was also ob-
served in fibroblasts surrounding non-neoplastic glands
(benign glands and PIN lesions) (see also Figure 3).
Key metabolism-related proteins in fibroblasts and
prostate glands across malignant transformation, i.e. from
BAFs to PAFs and finally CAFs, were investigated. MCT1
was clearly expressed in the plasma membrane of prostate
glands, but not the surrounding stroma. In contrast, the
expression of MCT4 increased in fibroblasts with increas-
ing degree of malignant transformation, but not in the
prostate glands. PDK1 expression was detected in both
glands and stroma, whereas CAIX was only detected in
stroma, with no staining in prostate glands (Figure 3).
Associations between the expression of the metabolic
proteins and clinico-pathological data are presented in
Table 2. We observed that CAIX expression in CAFsn in tumour cells and cancer associated fibroblasts (CAFs).
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Figure 2 Stacked bar graph according to one protein column within each fibroblast group for MCT4, PDK1 and CAIX expression. The
stronger expression (3) is represented by the more intense colour.
Pértega-Gomes et al. BMC Cancer 2014, 14:352 Page 4 of 8
http://www.biomedcentral.com/1471-2407/14/352was associated with biochemical recurrence after sur-
gery (p = 0.003). Furthermore, the strongest associations
identified were in samples with elevated levels of MCT1
in tumour cells together with elevated levels of MCT4 in
the surrounding CAFs. These cases were associated with
pT3 tumour stage (p = 0.009). Additionally, cases negative
for both MCT1 and MCT4, or positive for MCT1 in
the malignant glands and negative for MCT4 in CAFs,
showed no associations with clinico-pathological parame-
ters (data not shown).
Discussion
Several research groups have recently focused on the role
of CAFs in the progression and metastasis of prostate can-
cer, showing that a dynamic interaction between stroma
and epithelium might play a critical role in this progression
[14,15,22-25]. Thus, the essential role played by the cross-
talk between stroma and epithelium in carcinogenesis and
prostate cancer progression has been increasingly recog-
nised. In this work, we provide evidence for the possible
metabolic co-operation between cancer cells and the sur-
rounding fibroblasts by examining the expression of major
proteins involved in cellular metabolism. In particular, wefocus on differences between cancer cells and tumour-
associated fibroblasts, as well as between fibroblasts in dif-
ferent stages of malignant transformation, and examine
the possible clinico-pathological significance of the ex-
pression of these proteins.
By categorising the protein expression of stromal cells
associated with prostate cancer, we describe a com-
partment that is not well studied and will contribute to
an improved understanding of prostate cancer. We ob-
served significant differences between CAFs and tumour
glands with respect to the expression of key metabolic
proteins. In particular, CAIX and MCT4 selectively la-
belled cancer associated fibroblasts in contrast to malig-
nant glands, where CAIX and MCT4 were only present
in very few cases. On the other hand, a distinct, strong
membranous expression of MCT1 was consistently ob-
served in cancer cells, suggesting a role for MCT1 in the
transport of lactate into tumour cells from the acidic
extracellular matrix, suggesting that lactate might be
used as a fuel by oxidative cancer cells. We also ob-
served that proteins involved in fatty acid oxidation,
such as AMACR, ACOX-3 and DBP, were restricted to
the tumour cells, which is consistent with the presence
Figure 3 Immunohistochemical staining for MCT1, MCT4, PDK1 and CAIX expression in non-neoplastic tissue (NNT), PIN lesions (PIN),
tumour tissue (TT) and the surrounding stroma for each case. Strong expression of MCT4, PDK1 and CAIX in stromal cells is evident, in
contrast with MCT1, which is present only in the epithelial cells of the glands.
Table 2 Correlations between the key metabolic-related proteins MCT4, PDK1 and CAIX expressions in CAFs and
clinico-pathological data
MCT4 PDK1 CAIX MCT1/MCT4*
Variable n % p % p % p % p
PSA (ng/ml) 0.296 0.451 0.250 0.525
≤ 5.0 245 47.9 16.2 85.9 27.1
>5.0 123 44.0 17.5 82.2 27.5
pT 0.445 0.258 0.522 0.009
2 359 40.2 18.7 86.4 20.8
3 99 41.7 15.2 86.9 33.3
Perineural
Invasion 0.155 0.069 0.399 0.255
Absent 119 45.4 13.4 85.8 26.9
Present 327 39.4 19.8 87.2 23.3
Biochemical
Recurrence 0.104 0.176 0.003 0.052
Absent 410 40.2 18.5 75.4 22.6
Present 69 49.3 13.0 89.0 32.8
The correlation between MCT1/MCT4 expression (*MCT1 expression in prostate tumour cells with concomitant expression of MCT4 in CAFs) and the clinico-
pathological data is also presented.
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compatible with oxidative phosphorylation in prostate
cancer cells. It is important to note that fatty acid oxida-
tion is already considered a major source of acetyl-CoA
for the Krebs cycle [13], which further supports our
hypothesis.
The expression levels of GLUT1, a key glucose trans-
porter, define the rates of glucose influx into the cells.
In the present study, CAFs did not show GLUT1 or
GLUT-12 expression, and LDHV was also difficult to de-
tect. However, this possibly reflects the limits of the im-
munohistochemical technique to detect these proteins at
the baseline concentrations present in CAFs. Indeed, we
have previously found very few cases positive for GLUT-1
and GLUT-12, and this expression was not present at the
plasma membrane, suggesting a low level of activity of
these proteins in prostate cancer cells (unpublished re-
sults). Thus, assessment of other GLUT isoforms may be
worthwhile.
Interestingly, we also observed that protein expression
of MCT4, PDK1 and CAIX in prostate fibroblasts chan-
ges during malignant transformation, suggesting that the
existing stroma might also suffer alterations and play a
role in this metabolic adaptation of cancer cells beyond
the well-studied role of newly formed stroma.
From the above immunohistochemical findings, it seems
that well-organised metabolic regions composed of tu-
mour cells and CAFs may contribute to the ability of the
tumour to overcome the adverse microenvironment.
Our hypothesis is in agreement with those of Fiaschi
et al. [17], who describe the metabolic reprogramming
of CAFs towards the Warburg phenotype as a result ofFigure 4 Schematic representation of the lactate shuttle system betw
expression of MCT4 in CAFs together with the expression of MCT1 in tumo
pT3 stage of the tumour.contact with prostate cancer cells. Using in vitro studies,
they showed lactate production and efflux by de novo
expressed MCT4 in CAFs and also demonstrated that,
upon contact with CAFs, prostate cancer cells were repro-
grammed towards aerobic metabolism, with an increase in
lactate uptake via the lactate transporter MCT1. Further-
more, pharmacological inhibition of MCT1-mediated lac-
tate uptake dramatically affected PCa cell survival and
tumour outgrowth. However, in this study, no data regard-
ing clinico-pathological associations were shown, and few
cases were assessed. These findings are in contrast with
others ([18], which describe an energy recycling path be-
tween the aerobic stroma and the anaerobic cancer cells
within the framework of the Warburg effect. These con-
clusions are based mainly on the observation that LDH1
is evidently expressed in CAFs, and the presence of
MCT1 in prostate cancer cells was attributed to its role in
lactate efflux and not its uptake. We recognise the import-
ance of assessing LDH1; however, in our study we
assessed for the first time MCT4 and CAIX as important
markers of hypoxia in a larger cohort. Our findings cor-
roborate the work of Whitaker-Menezes et al. [16], who
described a “reverse Warburg effect,” where CAFs un-
dergo aerobic glycolysis to produce lactate, which is
subsequently used as a metabolic substrate by adja-
cent cancer cells. In this model, “energy transfer” or
“metabolic coupling” between the tumour stroma and
epithelial cancer cells fuels tumour growth and metas-
tasis via oxidative mitochondrial metabolism in anabolic
cancer cells. We believe that this is also the case in pros-
tate cancer, although more studies are needed to demon-
strate this.een malignant cells and cancer associated fibroblasts (CAFs). The
ur cells is associated with biochemical recurrence after surgery and
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rameters and found significant associations with poor
prognosis, raising once more the possible role of CAFs
in disease management. We believe that these changes
are likely to be a by-product of tumour biology with fur-
ther influence on patient outcomes that need to be ex-
plored more deeply.
In summary, we found differences between prostate
cancer cells and CAFs using tissues from 480 patients,
showing elevated expression of MCT4 and CAIX in CAFs
and demonstrating for the first time that the concomitant
expression of MCT1 in tumour cells and MCT4 in fibro-
blasts in the same tissue is clinically significant, and asso-
ciated with poor prognosis. Indeed, the stromal expression
of hypoxia-regulated proteins appears to be prognostic of
poor outcome in prostate carcinomas, suggesting that
tumour hypoxia may influence tumour-associated stromal
cells in a way that ultimately contributes to patient out-
come. Figure 4 shows a schematic representation of the
lactate shuttle between CAFs and PCa cells to illustrate
the hypothesis presented in our work.
Conclusions
In summary, we show for the first time that there is a
clinico-pathological significance for the MCT1/MCT4
lactate shuttle in prostate cancer. In fact, it seems that
the stromal expression of hypoxia-regulated proteins is
an adverse prognostic factor in prostate carcinomas,
suggesting that tumour hypoxia may influence tumour-
associated stromal cells in a way that ultimately contrib-
utes to patient prognosis.
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